Approval · Notice of Compliance 38023 · 2026
RAPAMUNE: Notice of Compliance 38023
Issued July 30, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38023
- Date
- July 30, 2026
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a drug product manufacturing site and/or manufacturer involving production
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RAPAMUNE | Not yet assigned | — |
Medicinal ingredients
- SIROLIMUS 1 MG per TAB